Contents

THE state of antioxidant defense system in patients with chronic heart failure,CAUSED BY DILATED CARDIOMYOPATHY

Sukoian G.V., Guchua E.I., Varazanashvili N.A., Vladickaia O.V. *,
 Janashia P.Ch. *, Karsanov N.V.
The NV Karsanov Repubican Research Centre of MedBiophysics and
Introduction of New Biomedical Technology, 
*Department of Internal Medicine, Moscow State University

In research on 36 patients with chronic heart failure (CHF) II - IV of a functional class of NYHA, caused by dilated cardiomyopathy (DCM), it has been  shown, that at manifested CHF the activity of superoxiddismutase, catalase and gluthationperoxidase, the enzymes of the antioxidant defense system is essentially reduced, whereas at CHF of a functional class II of NYHA raise. The similar changes occur in the contents of nonenzymatic link of antioxidant defense system: gluthatione and a-tocoferole. The decrease of the reserve ability of antioxidant defense system strengthening with decriasing of left ventricular dysfunction. These results once again have shown, that oxidative stress plays the important role in the transition of  unsymptomatic form of CHF in manifested and is associated with systolic and diastolic dysfunction and worsening of the prognosis of the СHF, caused by DCM. 

Literature:

1.       Иноятова Ф.Х., Иноятов Ф.Ш., Дададжанов Ш.Н. // Патология. 1998. №1. С.15-17.

2.       Королюк М.А., Иванова Л.И., Майорова И.Г., Токарев В.Е. // Лаб. дело. 1988; 1: 16-18.

3.       Мхитарян В.Г., Бадалян Г.Е. // Экспер. клин. мед. 1978; 6:7-11.

4.       Орлова Я.О. Мареев В.Е. Беленков Ю.Н. // Кардиология 1996 ; N 4.

5.       Рубина Х.М., Романчук Л.А. Вопр.мед.химии. - 1965. - №1. - С.27-31

6.       Belch JJ., Bridges AB., Scott N., et al. // Br. Heart J. 1991; 65:245-248.

7.       Burton KP. // Free Rad Biol Med. 1988; 4: 15-24.

8.       Cohn J.N., Ferrari R., Sharpe N. // J. Am. Coll Cardiol.  - 2000; 35: 569-580.

9.       Dhalla AK. Singal PK. Antioxidant changes in hyprtrophied and filling guinea pig hearts. Am.J.Physiol. 1994; 266:H1280-H1285.

10.   Daiz-Velez CR., Garcia-Castineiras S. Mendoza-Ramos E., et al. // Am Heart J. 1966; 131:146-152.

11.   Dhalla AK., Hill MF, Singal PK. // J.Am.Coll Cardiol. 1996; 28:506-514 -77

12.   Delanty N, Reilly MP, Pratico D, et al. // Circulation. 1997; 95:2492-2499

13.   Freeman B, Grapo J. // Lab. Invest. 1982; 43:412-426.

14.   Fridovich I. // Annu Rev Pharmacol Toxicol. 1983; 23:239-257.

15.   Fukuchi T, Kobayashi A, Kapeko M, et al.// Jpn Heart J. 1991; 32(5): 655-666.

16.   Ghatak A, Brar MJS, Agarwal A, et al. // Int J Cardiol. 1996; 57:119-127.

17.   Gupta M, Singal PK. // Circ Res. 1989; 64: 398-406.

18.   Hattori Y., Kawasaki H., Abe K., et al. // Am. J. Physiol. 1991; 261:H1086-H1094. -47

19.   Hill MF, Singal PK. // Am J Physiol. 1996; 148:291-300.

20.   Keith M., Geranmayegan A., Sole MJ., et al. //J. Am. Coll Cardiol. 1998; 31:1352-1356.

21.   Keith M., Khursheed NJ., Sole MJ. // Heart Failure.1999; 15: 179-187.

22.   Kirshenbaum LA, Singal PK. // Lab Invest. 1992; 76(6): 796-803.

23.   Mallat Z., Philip I., Lebret M., et al. // Circulation. 1998; 97:1536-1539.

24.   McMurray J, Chopra M, Abdullah I, et al. // Eur Heart J. 1993; 14:1493-1498.

25.   Munzel T., Harrison DG. // Circulation. 1999; 100:216-218.

26.   Stralin P., Karisson K., Johansson BO., et al. // Thromb. Vasc. Biol. 1995; 15:2032-2036.

27.   Sutton GC. // Am Heart J. 1990; 120:1538-1540

28.   Tesfamarian B., Cohen RA. // Am. J. Physiol. 1992; 263: H321-H326.

29.   Wamholtz A., Nickening G., Schultz E., et al. // Circulation. 1999; 99:2027-2033.

30.   Иноятова Ф.Х., Иноятов Ф.Ш., Дададжанов Ш.Н. // Патология. 1998. №1. С.15-17.

31.   Беленков Ю.Н., Агеева Ф.Т. Эпидемиология и прогноз хронической сердечной недостаточности // Рус. мед. журн. - 1999. - № 2. - С. 51-55.

32.   Королюк М.А., Иванова Л.И., Майорова И.Г., Токарев В.Е. // Лаб. дело. 1988; 1: 16-18.

33.   Мхитарян В.Г., Бадалян Г.Е. // Экспер. клин. мед. 1978; 6:7-11.

34.   Орлова Я.О. Мареев В.Е. Беленков Ю.Н. // Кардиология 1996 ; N 4.

35.   Рубина Х.М., Романчук Л.А. Вопр.мед.химии. - 1965. - №1. - С.27-31

36.   Belch JJ., Bridges AB., Scott N., et al. Oxygen free radicals and congestive heart failure. Br. Heart J. 1991; 65:245-248. -52

37.   Burton KP.Evidence of direct toxic effects of free radicals on the myocardium. Free Rad Biol Med. 1988; 4: 15-24.

38.   Cohn J.N., Ferrari R., Sharpe N. // J. Am. Coll Cardiol.  - 2000. – Vol. 35. – P. 569-580.

39.   Сowburn P.J., Cleland J.G.F., Coats A.I.S. Komajda M. // Eur. Heart  J. -  1998. – Vol. 19. – P. 696-710.

40.   Dhalla AK. Singal PK. Antioxidant changes in hyprtrophied and filling guinea pig hearts. Am.J.Physiol. 1994; 266:H1280-H1285. -53

41.   Daiz-Velez CR., Garcia-Castineiras S. Mendoza-Ramos E., et al. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J. 1966; 131:146-152 -67

42.   Dhalla AK., Hill MF, Singal PK. Role of oxidative stress in the transition from hypertrophy to heart failure. J.Am.Coll Cardiol. 1996; 28:506-514 -77

43.   Delanty N, Reilly MP, Pratico D, et al. 8-Epi PGF2a generation during reperfusion: a potential quantitative marker of oxidant stree in vivo. Circulation. 1997; 95:2492-2499

44.   Freeman B, Grapo J. Biology disease – free radicals and tissue injury. Lab. Invest. 1982; 43:412-426.

45.   Fridovich I. Superoxide radical: An endogenous toxicant. Annu Rev Pharmacol Toxicol. 1983; 23:239-257.

46.   Fukuchi T, Kobayashi A, Kapeko M, et al. Possible involvement of free radicals in the early stages of the development of cardiomyopathy in BIO 14.6 Syrian Hamster. Jpn Heart J. 1991; 32(5): 655-666 -102

47.   Ghatak A, Brar MJS, Agarwal A, et al. Oxy free radical system in heart failure and therapeutic role of oral vitamin E. Int J Cardiol. 1996; 57:119-127.

48.   Gupta M, Singal PK. Higher antioxidant capacity during chronic stable heart fypertrophy. Circ Res. 1989; 64: 398-406 - 101

49.   Hattori Y., Kawasaki H., Abe K., et al. Superoxide dismutase recoveres altered endothelium dependent relaxation in diabetic rat aorta. Am. J. Physiol. 1991; 261:H1086-H1094. -47

50.   Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Physiol. 1996; 148:291-300 - 98

51.   Keith M., Geranmayegan A., Sole MJ., et al. Increased oxidative stress in patients with congestive heart failure. J. Am. Coll Cardiol. 1998; 31:1352-1356.

52.   Keith M., Khursheed NJ., Sole MJ. // Heart Failure.1999; 15: 179-187.

53.   Kaul N., Siveski-Iliskovic N., Hill M., et al. Free radicals and the heart. J.Pharmacol Toxicol Meths. 1993; 30:55-67 -63

54.   Kirshenbaum LA, Singal PK. Changes in antioxidant enzymes in isolated cardiac myocytes subjected to hypoxia-reoxygenation. Lab Invest. 1992; 76(6): 796-803 - 90

55.   Mallat Z., Philip I., Lebret M., et al. Elevated levels of 8-iso prostaglandin F2a in pericardial fluid of patients with heart failure. Circulation. 1998; 97:1536-1539.-68

56.   McMurray J, Chopra M, Abdullah I, et al. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J. 1993; 14:1493-1498.

57.   Munzel T., Harrison DG. Increased superoxide in heart failure: A biomedical baroreflex gone awry. Circulation. 1999; 100:216-218 -50

58.   Stralin P., Karisson K., Johansson BO., et al. The interstitium of the human arterial wall contains very large amount of extracellular superoxide dismutase. Arterioscler. Thromb. Vasc. Biol. 1995; 15:2032-2036. -42

59.   Sutton GC. Epidemiologic aspects of heart failure. Am Heart J. 1990; 120:1538-1540

60.   Tesfamarian B., Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am. J. Physiol. 1992; 263: H321-H326. -48

61.   Wamholtz A., Nickening G., Schultz E., et al. Hyperholesterolemia increases endothelial superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system. Circulation. 1999; 99:2027-2033.

 

Contents